News
Public · Published
Truist Securities maintains Hinge Health at Buy, raises price target to $145 from $112
Truist Securities kept its Buy rating on Hinge Health and raised its price target to $145 from $112, a 29.5% increase. The new target implies 25.6% upside from the Nov 2 close of $115.48.
Published:
Updated:
What happened
Truist Securities kept its Buy rating on Hinge Health and raised its price target to $145 from $112, a 29.5% increase. The new target implies 25.6% upside from the Nov 2 close of $115.48.
Confirmed
Global impact / market context
A higher price target signals that Truist expects more future value from Hinge Health, which can draw investor attention toward the stock and support its share price as buyers weigh the analyst's more optimistic view against the current price.
Analyst inference
Other recent analyst notes put price targets for Hinge Health between $132 and $150, all above the Nov 2 close. That clustering of higher targets suggests broad analyst confidence and may shape how investors position the stock.
Analyst inference
What to watch
- Truist's $145 target implies 25.6% upside from the Nov 2 close of $115.48, so watch whether the share price moves toward that level. Confirmed
- Track whether other analysts change their $132 to $150 targets; matching moves would reinforce the optimistic view, while cuts would weaken it. Analyst inference
- Watch for any company updates on revenue, costs, or cash available, since analysts may adjust ratings and targets if those results differ from expectations. Proposed
Evidence
- Original source link unavailable